Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Oct
13
Today In Oncology
Insurance and Cost Barriers to Oral Therapies for Blood Cancers
Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer
Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes
The Wistar Institute Names New President and Chief Executive Officer
Early Research Links Abdominal Obesity to Increased Lung Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo